<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797299</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2021-ELISA</org_study_id>
    <nct_id>NCT04797299</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)</brief_title>
  <acronym>ELISA</acronym>
  <official_title>Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether the combination of clinicopathological factors and the use of the&#xD;
      Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast&#xD;
      conserving surgery (BCS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective cohort study, conducted in Canada, to prospectively evaluate whether the&#xD;
      combination of clinicopathological criteria and the Oncotype DX DCIS score can identify a&#xD;
      group of women at very low risk of local recurrence following breast conserving surgery who&#xD;
      do not require breast radiation therapy. We plan to screen 809 consenting women who will have&#xD;
      their tumour tissue specimen sent to Exact Sciences to assess their DCIS score. We anticipate&#xD;
      that 526 women will have an Oncotype DX DCIS score &lt;39 and a predicted 10-year risk of local&#xD;
      recurrence &lt;10%, these patients will be enrolled and followed as part of the study.&#xD;
&#xD;
      At each centre, all patients with DCIS referred to radiation oncology will be documented.&#xD;
      When a physician identifies an eligible patient, the patient will be approached by the&#xD;
      referring physician or delegate to voluntarily provide informed consent to participate in&#xD;
      this study. Consenting patients will be registered through the Ontario Clinical Oncology&#xD;
      Group's (OCOG) web-based registration system. A two-step registration/enrollment process will&#xD;
      be implemented.&#xD;
&#xD;
      Data related to the patient demographics, surgery details, tumour characteristics and ECOG&#xD;
      performance will be collected. The patient's tumour specimen will be sent for analysis to&#xD;
      Exact Sciences. The DCIS score results will be sent to the referring physician. OCOG will&#xD;
      also receive the DCIS score results. Patients will be followed every 6 months for the first 2&#xD;
      years and then yearly up to 10 years. Bilateral mammograms will be performed 6 months after&#xD;
      BCS and then annually. The study data will be verified by source documentation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2034</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2034</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ipsilateral local recurrence (LR)</measure>
    <time_frame>5 Year</time_frame>
    <description>Defined as recurrent invasive or in situ cancer in the ipsilateral breast</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral invasive local recurrence</measure>
    <time_frame>5 Year</time_frame>
    <description>defined as time from study registration to time of recurrent invasive cancer in the ipsilateral breast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer recurrence-free interval (RFI)</measure>
    <time_frame>5 Year</time_frame>
    <description>defined as time from study registration to time of documented recurrent disease (ipsilateral breast (DCIS or invasive), regional, distant or death from breast cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant disease-free survival (DDFS)</measure>
    <time_frame>5 Year</time_frame>
    <description>defined as time from study registration to distant recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>5 Year</time_frame>
    <description>defined as time from registration to time of LR (DCIS or invasive), regional and distant recurrence, contralateral breast cancer, new primary (non-breast) and death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 Year</time_frame>
    <description>defined as time from registration to death of any cause</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">526</enrollment>
  <condition>DCIS</condition>
  <arm_group>
    <arm_group_label>Single Arm Cohort</arm_group_label>
    <description>Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens will be used to determine Oncotype DX DCIS Score and subsequent testing for future&#xD;
      correlative studies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective cohort study conducted in Canada in women with a low risk DCIS following breast&#xD;
        conserving surgery who are candidates for radiation.&#xD;
&#xD;
        Eligibility status should be confirmed by the referring physician or delegate prior to&#xD;
        enrollment. It is important that no exceptions are made to the eligibility criteria.&#xD;
        Questions related to eligibility requirements and/or specific criteria should be addressed&#xD;
        with OCOG prior to enrollment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patient &gt; 45 years of age with DCIS without microinvasion.&#xD;
&#xD;
          2. Tumour size ≤ 2.5cm.&#xD;
&#xD;
          3. Treated by BCS with clear resection margins ≥ 2 mm or no residual disease on&#xD;
             re-excision.&#xD;
&#xD;
          4. Oncotype DX DCIS score &lt; 39 and predicted 10-year risk of LR &lt;10%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multifocal DCIS.&#xD;
&#xD;
          2. History of any invasive breast cancer or non-invasive breast cancer in the ipsilateral&#xD;
             breast.&#xD;
&#xD;
          3. Prior history of invasive cancer within the last 5 years.&#xD;
&#xD;
          4. ECOG performance status ≥3 (Appendix II).&#xD;
&#xD;
          5. Life expectancy &lt;10 years.&#xD;
&#xD;
          6. Geographic inaccessibility for follow-up.&#xD;
&#xD;
          7. Inability to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Whelan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eileen Rakovitch, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Research Institute, Sunnybrook Health Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciana Spadafora</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42655</phone_ext>
    <email>spadafl@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Nason</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42622</phone_ext>
    <email>nason@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Tim Whelan, M.D</last_name>
      <phone>905-387-9711</phone>
      <email>twhelan@hhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Richardson</last_name>
      <phone>905-387-9495</phone>
      <phone_ext>64432</phone_ext>
      <email>srichard@hhsc.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario, Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Conrad Falkson, M.D.</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>4509</phone_ext>
      <email>conrad.falkson@kingstonhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Lindsay</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>6654</phone_ext>
      <email>lindsayc@kgh.kari.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Francisco Perera, M.D.</last_name>
      <phone>519-685-8650</phone>
      <email>francisco.perera@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Petrie</last_name>
      <phone>519-685-8618</phone>
      <email>rebecca.petrie@lhsc.on.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Walker Family Cancer Centre, Niagara Health System,St. Catharines</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2S 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Abhirami Hallock, M.D.</last_name>
      <phone>905-684-7271</phone>
      <phone_ext>43801</phone_ext>
      <email>hallock@hhsc.ca, abhirami.hallock@jcc.hhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Joanne Haun</last_name>
      <phone>1-905-684-7271</phone>
      <phone_ext>45703</phone_ext>
      <email>joanne.haun@niagarahealth.on.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care, Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Margaret Anthes, M.D.</last_name>
      <phone>807-684-7566</phone>
      <email>anthesm@tbh.net</email>
    </contact>
    <contact_backup>
      <last_name>Lori Moon</last_name>
      <phone>807-684-7226</phone>
      <email>moonl@tbh.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre -Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Eileen Rakovitch, M.D.</last_name>
      <phone>416-480-4806</phone>
      <email>eileen.rakovitch@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sabina Trebinjac</last_name>
      <phone>416.480.5000</phone>
      <phone_ext>87031</phone_ext>
      <email>sabina.trebinjac@sunnybrook.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Koch, M.D.</last_name>
      <phone>416-946-4662</phone>
      <email>anne.koch@rmp.uhn.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ocog.ca</url>
    <description>OCOG website accessed by clinical centres</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ductal Carcinoma in Situ</keyword>
  <keyword>Breast Conserving Surgery</keyword>
  <keyword>Oncotype DX DS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

